# Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

> **NCT06391034** · PHASE2 · RECRUITING · sponsor: **Robert Bok, MD, PhD** · enrollment: 161 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** hyperpolarized pyruvate +/-urea (13C/15N)
- **RADIATION:** Non-investigational External beam radiotherapy (EBRT)
- **PROCEDURE:** Radiotherapy (RT)
- **PROCEDURE:** Multi-parametric magnetic resonance imaging (mpMRI)
- **BIOLOGICAL:** Non-interventional hormone therapy
- **PROCEDURE:** Prostate Biopsy

## Key facts

- **NCT ID:** NCT06391034
- **Lead sponsor:** Robert Bok, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2028-12-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 161 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391034, "Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06391034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*